• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Boston Scientific

Data backs Boston Scientific drug-eluting stent

April 23, 2025 By Sean Whooley

Boston Scientific Eluvia drug-eluting vascular stent system (1)

Boston Scientific today shared study data supporting the use of its Eluvia drug-eluting stent for treating PAD. The company shared multiple new clinical data sets at Charing Cross 2025 in London today. Findings reinforced the growing body of evidence supporting the Eluvia stent for treating peripheral artery disease (PAD) — particularly in the superficial femoral […]

Filed Under: Cardiovascular, Clinical Trials, Drug-Device Combinations, Featured, Implants, Stents, Vascular Tagged With: Boston Scientific

Boston Scientific to acquire hepatic artery infusion pump maker Intera Oncology

November 25, 2024 By Sean Whooley

Boston Scientific Intera Oncology

Boston Scientific (NYSE:BSX) announced today that it agreed to acquire infusion pump maker Intera Oncology for an undisclosed amount. Intera Oncology develops the Intera 3000 hepatic artery infusion pump and floxuridine, a chemotherapy drug. Both hold FDA approval. The pump administers hepatic artery infusion (HAI) therapy to treat tumors in the liver primarily caused by […]

Filed Under: Business/Financial News, Drug-Device Combinations, Featured, Mergers & Acquisitions, Oncology Tagged With: Boston Scientific, Intera Oncology

Boston Scientific has positive Agent DCB study results

March 11, 2024 By Sean Whooley

Boston Scientific Agent drug-coated balloon DCB

Boston Scientific [WtwhTicker symbol=”BSX”](NYSE: BSX)[/WtwhTicker] reported positive investigational device exemption (IDE) trial data for its Agent drug-coated balloon (DCB). The DCB just this month won FDA approval for treating coronary in-stent restenosis (ISR) in patients with coronary artery disease. ISR occurs when plaque or scar tissue obstructs or narrows a stented vessel. Agent serves as […]

Filed Under: Cardiovascular, Drug-Device Combinations, Featured Tagged With: Boston Scientific

FDA approves Boston Scientific’s Agent drug coated balloon

March 1, 2024 By Sean Whooley

Boston Scientific Agent drug-coated balloon DCB

Boston Scientific [WtwhTicker symbol=”BSX”](NYSE: BSX)[/WtwhTicker] announced today that it received FDA approval for its Agent drug-coated balloon (DCB). The DCB won approval for treating coronary in-stent restenosis (ISR) in patients with coronary artery disease. ISR occurs when plaque or scar tissue obstructs or narrows a stented vessel. Marlborough, Massachusetts-based Boston Scientific plans a U.S. launch for […]

Filed Under: Cardiovascular, Drug-Device Combinations, Featured, Food & Drug Administration (FDA), Regulatory/Compliance, Vascular Tagged With: Boston Scientific, FDA

Boston Scientific shares positive drug-coated balloon data

October 27, 2023 By Sean Whooley

Boston Scientific Agent drug-coated balloon DCB

Boston Scientific [WtwhTicker symbol=”BSX”](NYSE: BSX)[/WtwhTicker] announced positive data from a trial of its Agent drug-coated balloon (DCB). The Marlborough, Massachusetts-based company presented its results at the Transcatheter Cardiovascular Therapeutics (TCT) meeting. Data demonstrated statistical superiority for Agent compared to uncoated balloon angioplasty. AGENT IDE evaluated the safety and effectiveness of using a DCB to treat […]

Filed Under: Cardiovascular, Clinical Trials, Drug-Device Combinations, Featured Tagged With: Boston Scientific

Boston Scientific hit with $42M verdict in drug-eluting stents IP case

February 2, 2023 By Chris Newmarker

Pixabay stock image of a gavel to go with Boston Scientific drug-eluting stents IP verdict story

Boston Scientific (NYSE:BSX) must pay $42 million in unpaid royalties to TissueGen and the University of Texas, a federal jury in Delaware has ruled. The jury verdict yesterday came after the finding that Boston Scientific’s Synergy BP drug-eluting stents infringed on TissueGen and the university’s IP. The patent under question arose out of research that […]

Filed Under: Featured, Legal News, Stents Tagged With: Boston Scientific, TissueGen

Boston Scientific to acquire majority stake in interventional tech developer Acotec

December 12, 2022 By Sean Whooley

Boston Scientific

Boston Scientific (NYSE:BSX) announced that it intends to make a partial offer to acquire a majority stake in Acotec. Marlborough, Massachusetts-based Boston Scientific’s offer could add up to a maximum of 65% of Acotec’s shares. Its proposed price totals HK$20 per share. That amounts to approximately $523 million for the 65% stake at current exchange […]

Filed Under: Business/Financial News, Drug-Device Combinations, Mergers & Acquisitions, Vascular, Wall Street Beat Tagged With: Acotec, Boston Scientific

Boston Scientific warns on some SpaceOAR systems

March 21, 2022 By Sean Whooley

Boston Scientific

Boston Scientific (NYSE:BSX) has issued an urgent field safety notice in Europe due to potential issues with its SpaceOAR systems. Marlborough, Massachusetts-based Boston Scientific’s SpaceOAR system is an absorbable polyethylene glycol hydrogel spacer for separating the prostate from the rectal wall during radiation treatment for prostate cancer. The SpaceOAR Vue, the next-generation hydrogel spacer, offers enhanced […]

Filed Under: Featured, Hydrogels, Oncology, Radiosurgery, Recalls, Regulatory/Compliance Tagged With: Boston Scientific

First patients enrolled in trial for Boston Scientific’s SpaceOAR Vue hydrogel

February 10, 2022 By Sean Whooley

Boston Scientific

GenesisCare announced today that it enrolled the first patients in a trial for Boston Scientific’s (NYSE:BSX) SpaceOAR Vue hydrogel. Boston Scientific’s SpaceOAR Vue hydrogel will be evaluated in the SABRE trial, sponsored by Boston Scientific, for prostate cancer patients receiving stereotactic body radiation therapy (SBRT). Get the full story at our sister site, MassDevice.

Filed Under: Clinical Trials, Featured, Hydrogels, Oncology Tagged With: Boston Scientific

Boston Scientific touts data from Phase 3 study of selective internal radiation therapy

September 20, 2021 By Sean Whooley

Boston Scientific

Boston Scientific (NYSE:BSX) today touted data from a Phase 3 clinical trial of its TheraSphere Y-90 glass microspheres treatment. In the trial, the TheraSphere treatment successfully met both primary endpoints, including progression-free survival (PFS) and hepatic progression-free survival (hPFS) in patients with metastatic colorectal cancer (mCRC) of the liver. Marlborough, Mass.-based Boston Scientific’s TheraSphere treatment, […]

Filed Under: Clinical Trials, Drug-Device Combinations, Featured, Immunotherapy, Oncology Tagged With: Boston Scientific

  • Page 1
  • Page 2
  • Page 3
  • Interim pages omitted …
  • Page 6
  • Go to Next Page »

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS